Moderna (MRNA) R&D Day Highlights Progress and Strategic Priorities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P 500, Dow futures muted ahead of jobs data; chips, software stocks rise
- Oil prices drop as investors weigh potential Hormuz deal between Iran, Gulf states
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Why a solid NFP report could spark a stock selloff, according to JPMorgan
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Moderna R&D Day Highlights Progress and Strategic Priorities
September 12, 2024 6:02 AM EDTFocuses on ten product approvals through 2027
Expects to submit next-generation COVID vaccine for approval in 2024
Expects to submit flu/COVID combination vaccine for approval in 2024
Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024
Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparator
Announces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal... More
